Obermatt
See Similar Stocks →

Flags

Earnings warning

Mochida Pharmaceutical

TYO:4534 · JP3922800002
PharmaceuticalsMedium

360

65
Medium confidence — indicative
EV / EBIT82
Price / Owner Earnings32
Owner Earnings Yield78
Dividend Yield1
Price/Sales67
EV / Gross Profit84
Price/Book79
Return on Capital67
Cash Return on Capital58
Return on Equity54
EBIT Margin58
Gross Profitability61
Cash Conversion9
Accruals11
Owner Earnings Margin59
Sales growth73
Profit Growth79
Long-Term EPS Growth62
Reinvestment68
Price momentum81
Debt load83
Refinancing74
Debt Payback100
Liquidity93
Analyst ratings8
Expectations trend50
Market mood55
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Mochida Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryJapan
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeTSE
Founded1945
Employees11
Websitemochida.co.jp
ISINJP3922800002
Last UpdateApr 2, 2026
Index & Theme
PsychiatryCardiovascularRheumatologyDermatologyGastroenterologyHealth CareMedicalPharmaceutical

Description

Analysis

Bargain bin

Mochida Pharmaceutical Co., Ltd. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 13.0×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 13/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
82
2023202420252026

All-time high

82

Jun 2026

All-time low

41

Jan 2023

Average rank

62

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
67
83
83
82
Price/Earnings
66
54
67
73
Price/Book
79
89
84
84
Dividend Yield
1
74
73
57
Value (overall)
57
86
88
81

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Mochida Pharmaceutical with its peers
Daiichi Sankyo
TYO:4568
56
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
CSPC Pharmaceutical
HKG:1093
79
CountryChina
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Hyundai Pharmaceutical
KSC:004310
33
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Shionogi
TYO:4507
70
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
HUTCHMED (China)
HKG:13
27
CountryHong Kong SAR China
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Yuhan
KSC:000100
32
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →